in this issue
Regions :: Western Europe :: Switzerland
Lonza Rides Biopharma Wave
12:09 PM MDT | July 30, 2007 | Alex Scott
Lonza has unveiled a robust set of 2006 results, bolstered by a substantial contribution from the company’s fast-growing biopharmaceuticals business. Lonza’s biopharma sales increased 31% last year, to SF468 million ($375 million), the company says. Growing demand and a strong project pipeline supported a number of capacity expansions and related acquisitions in the biopharma field, Lonza says. Lonza’s exclusive synthesis and biopharmaceuticals division, which includes the biopharma business, recorded a 36% increase in 2006 Ebit, to SF193...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee